Lumexa Q3: Net Income Turns Positive at $7.2M, Adjusted EPS Guidance Raised to $0.86-$0.90
LMRI has more than doubled off its 52-week low of $6.45.
Summary
Lumexa reported Q3 2026 net income of $7.2 million versus a $3.5 million loss a year ago, with Adjusted EBITDA of $62.6 million. Full-year Adjusted EPS guidance rose to $0.86-$0.90 on a lower tax rate, while the Adjusted EBITDA range was merely narrowed around an unchanged $238 million midpoint.
Key Events · Earnings and Guidance · LMRI
-
Q3 Revenue Up 5.0% to $272.0M
Consolidated revenue rose to $272.0 million from $258.9 million, with system-wide growth of 7.7% and advanced outpatient volume up 7.9% consolidated.
-
Net Income Turns Positive at $7.2M
Net income of $7.2 million versus a $3.5 million net loss a year earlier; GAAP EPS of $0.07 and Adjusted EPS of $0.26. Interest expense fell to $15.7 million from $30.6 million.
-
Adjusted EPS Guidance Raised
Full-year 2026 Adjusted EPS guidance lifted to $0.86-$0.90 from $0.71-$0.77, driven by a lower assumed effective tax rate rather than operating improvement.
-
EBITDA Range Narrowed, Midpoint Flat
Adjusted EBITDA guidance narrowed to $236-$240 million from $235-$241 million, midpoint unchanged at $238 million; $7 million of new public-company costs cut 2026 growth to 4% from 7%.
Analysis · LMRI · Industrial Applications And Services
The swing from a $3.5 million net loss to $7.2 million of net income is the quarter's most striking line, helped by interest expense falling to $15.7 million from $30.6 million; nine-month operating cash flow also flipped to $70.5 million from roughly breakeven. Guidance is where the nuance sits. Adjusted EPS was raised to $0.86-$0.90 from $0.71-$0.77, but the driver is a lower assumed tax rate, not better operations. Adjusted EBITDA guidance was only narrowed to $236-$240 million, with the $238 million midpoint unchanged, and management notes that $7 million of new public-company costs cut 2026 Adjusted EBITDA growth to 4% from 7%. Revenue guidance of $1.045-$1.097 billion was reiterated, so the quarter reads as a solid, cash-generative confirmation rather than an upgrade to the operating story.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LMRI was trading at $13.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $6.45 to $19.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.